Chagas Disease Management

Diagnostic Methods

• The diagnosis of Chagas disease requires a combination of two positive serological tests using different antigens, with ELISA and immunofluorescence assay (IFA) being the preferred methods for chronic infection detection in individuals from endemic areas, such as Latin America, and the American Heart Association recommends IFA for its high specificity when combined with ELISA 1, 2
• ELISA has high sensitivity (95-99%) for detecting IgG antibodies in individuals with chronic Chagas disease, and is a key component of the diagnostic protocol 2, 3
• NAAT (Nucleic Acid Amplification Test) requires 1.0 mL venipuncture blood in EDTA tube, with transport considerations including testing ASAP and refrigeration for up to 48 hours, and a turnaround time of 1-2 hours 3
• IFA (immunofluorescence assay) is a serological method with high specificity when combined with ELISA, and is recommended by the American Heart Association for diagnosis, along with epidemiological risk assessment and evaluation for cardiac involvement 1, 3

Screening Recommendations

• Screening should be considered for persons from endemic areas (Latin America), children of mothers from endemic areas, and individuals with epidemiological risk factors, such as history of residence in rural endemic areas, exposure to precarious housing, or history of blood transfusion in endemic countries, as recommended by Eurosurveillance and the American Heart Association 2, 1
• Key elements to suspect the disease include a history of residence in rural endemic areas, exposure to precarious housing, history of blood transfusion in endemic countries, and being the child of a mother with Chagas disease, as recommended by the CDC, the American College of Cardiology, the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) 3, 4

Diagnostic Challenges

• Direct detection methods have limited utility in chronic phase due to low parasitemia, and only 1-2% of infected individuals present with symptoms during the acute stage 2, 3
• The CDC provides a telediagnostic consultation service for diagnostic challenges, and recommends considering epidemiological risk factors for Chagas disease suspicion 3, 4

Cardiac Complications

• ECG and echocardiogram should be used to detect cardiac complications, including right bundle branch block, left anterior fascicular block, complete atrioventricular block, complex ventricular arrhythmias, apical aneurysm, ventricular function, and biventricular enlargement, as recommended by the American Heart Association 1
• Patients with established cardiac involvement should avoid intense competitive sports, as recommended by the American College of Cardiology (ACC) 5

Treatment and Follow-up

• Treatment should be initiated with Benznidazole (first-line) or Nifurtimox (alternative) as soon as diagnosis is confirmed, particularly in cases of acute infection, congenital infection, reactivation, early chronic phase, and most patients in chronic phase without advanced cardiopathy, as stated by the Infectious Diseases Society of America (IDSA) and the World Health Organization 3, 4, 6
• Antiparasitic treatment is indicated in all cases of acute infection, congenital infection, reactivation, and early chronic phase, and should be considered in most patients in the chronic phase without advanced cardiopathy, with prior treatment with benznidazol significantly reducing the risk of reactivation (OR 0.12; 95% CI: 0.02-0.76) 3, 4, 6
• Clinical evaluation every 14 days is recommended for patients undergoing treatment for Chagas disease, along with serological tests for follow-up, as stated by the CDC and the WHO 3, 4
• Regular follow-up is required for patients in the indeterminate phase, as 10-30% will develop symptomatic disease, and patients with positive serology without cardiac or gastrointestinal involvement are considered to be in the indeterminate phase, requiring regular follow-up 1, 3

Organ Donation

• Acute infection is an absolute contraindication for donation of any organ, according to the Centers for Disease Control and Prevention 7
• Chronic treated infection allows for selective organ donation, as per the World Health Organization guidelines, with the following recommendations:

• The recipient of an organ from a donor with treated Chagas disease should undergo parasitological monitoring with PCR to detect early reactivation or transmission, as recommended by the Infectious Diseases Society of America, with close monitoring required during the first 6 months post-transplant, when the risk of reactivation is highest (32%; 95% CI: 17-58%) 6
• Immunosuppression increases the risk of reactivation, according to the European Society of Clinical Microbiology and Infectious Diseases, and each episode of rejection increases the risk of reactivation (HR 1.31; 95% CI: 1.06-1.62) 2, 6